(Información remitida por la empresa firmante)
HELLERUP, Denmark, April 21, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced participation at the Kempen Life Science Conference on April 25-26, 2023, in Amsterdam.
ContactsMorten Boesen, Chief Financial Officer, UNION therapeutics A/S+45 2381 email@example.comSarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S+45 5385 firstname.lastname@example.org
About UNION therapeutics
UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-to-participate-at-kempen-life-science-conference-301804056.html